Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the recipient of unusually large options trading activity on Thursday. Traders acquired 4,052 call options on the company. This is an increase of approximately 103% compared to the average volume of 1,999 call options.

Reviva Pharmaceuticals Trading Up 2.2 %

NASDAQ:RVPH traded up $0.04 during mid-day trading on Thursday, hitting $1.85. 637,940 shares of the company’s stock were exchanged, compared to its average volume of 796,415. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $5.67. The company has a 50 day simple moving average of $1.45 and a 200-day simple moving average of $1.26. The firm has a market capitalization of $61.87 million, a P/E ratio of -1.67 and a beta of -0.02.

Wall Street Analyst Weigh In

Separately, EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 23rd.

Institutional Trading of Reviva Pharmaceuticals

A hedge fund recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.